Daniel Wainstein
Voorzitter bij STELLA DIAGNOSTICS INC.
Vermogen: 506 $ op 30-04-2024
Profiel
Daniel Wainstein is currently the Chairman at Stella Diagnostics, Inc., Chairman at Chain Bridge I, and Owner at Seven Knots LLC.
Previously, he worked as the Chief Executive Officer at JMD Properties, Inc. and as a Director at Varian Biopharmaceuticals, Inc. He completed his undergraduate degree at Hofstra University in 2001 and his graduate degree at Maurice A.
Deane School of Law at Hofstra University in 2006.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
STELLA DIAGNOSTICS INC.
0.08% | 30-06-2022 | 7 030 ( 0.08% ) | 506 $ | 30-04-2024 |
Actieve functies van Daniel Wainstein
Bedrijven | Functie | Begin |
---|---|---|
STELLA DIAGNOSTICS INC. | Voorzitter | - |
CHAIN BRIDGE I | Voorzitter | 01-01-2024 |
Seven Knots LLC | Corporate Officer/Principal | - |
Eerdere bekende functies van Daniel Wainstein
Bedrijven | Functie | Einde |
---|---|---|
Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Directeur/Bestuurslid | - |
JMD Properties, Inc.
JMD Properties, Inc. Medical SpecialtiesHealth Technology JMD Properties, Inc. is a content conversion service provider, developer, and integrator for the 3D Stereo and auto-stereo media industry. Its services include proprietary 3D reality splitter 2D to 3D conversion; stereo and multi-view consulting and integration; value added reseller of turnkey multi-view systems for digital signage. The company was founded in 1989 and is headquartered in Cheyenne, WY. | Algemeen Directeur | - |
Opleiding van Daniel Wainstein
Hofstra University | Undergraduate Degree |
Maurice A. Deane School of Law at Hofstra University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
CHAIN BRIDGE I | Finance |
STELLA DIAGNOSTICS INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
JMD Properties, Inc.
JMD Properties, Inc. Medical SpecialtiesHealth Technology JMD Properties, Inc. is a content conversion service provider, developer, and integrator for the 3D Stereo and auto-stereo media industry. Its services include proprietary 3D reality splitter 2D to 3D conversion; stereo and multi-view consulting and integration; value added reseller of turnkey multi-view systems for digital signage. The company was founded in 1989 and is headquartered in Cheyenne, WY. | Health Technology |
Seven Knots LLC | |
Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Health Technology |